Combined Review with the MHRA for CTIMPs

From 01 January 2022, a single application process with the MHRA will apply for new Clinical Trials of Investigational Medicinal Products (CTIMPs) in the UK. This combined review brings together Clinical Trial Authorisation and REC opinion, resulting in a single UK decision for CTIMPs. Sponsors and researchers are encouraged to become familiar with the new process through a step by step guide to using IRAS for Combined Review.